Association of testosterone deficiency and insulin resistance with prostate cancer severity in patients with type 2 diabetes mellitus
Background. In patients with type 2 diabetes mellitus, insulin resistance and testosterone deficiency may interact to accelerate and worsen prostate cancer. The purpose of the study was to examine the correlation between testosterone deficiency and insulin resistance with the extent of prostate cancer in individuals with type 2 diabetes mellitus and to test whether the two are potential predictive biomarkers of disease progression. Materials and methods. The case-control study was carried out between January 2025 and February 2026 in Iraqi specialized clinics to determine the relationship between testosterone deficiency and insulin resistance and the severity of prostate cancer in patients with type 2 diabetes mellitus. One hundred and fifty individuals (100 patients and 50 controls) were involved. Clinical, biochemical and histopathological criteria were used to diagnose it. Blood samples were taken and biochemical, hormonal indices and insulin resistance were measured by enzyme-linked immunosorbent assay and automated analyzers. Results. The age and smoking status did not show any significant differences whereas body mass index, waist circumference, blood pressure, family history and physical inactivity significantly increased in patients. Metabolic and endocrine changes were lower testosterone and high glucose, insulin, HOMA-IR, glycated hemoglobin, prostate specific antigen, and dyslipidemia (p < 0.001). The severity of the disease was linked to the reduction in testosterone and the rise in the metabolic markers (p < 0.001). There was a strong correlation and regression, which validated testosterone deficiency and insulin resistance as important predictors of prostate cancer severity in patients with type 2 diabetes mellitus. Conclusions. Testosterone deficiency and insulin resistance interact to increase the severity of prostate cancer in type 2 diabetes mellitus patients, probably because of insulin-like growth factor-1 signaling, chronic inflammation, and hormonal imbalance, which facilitate tumor growth, metabolic dysregulation, and further progression to more aggressive disease phenotypes.
Authors
- Fatima MOHAMMED (ORCID: https://orcid.org/0000-0001-5106-319X)
- Zainab M. Qassam (ORCID: https://orcid.org/0009-0009-5263-7461)
- Osama Akram Mohsein
- Aya Khudhair Khalaf
Institutions
- Ministry of Health (IQ)
- University of Diyala (IQ)
Publication Details
- Journal
- INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Published
- 2026-11-14
- DOI
- https://doi.org/10.22141/2224-0721.22.7.2026.1783
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00